Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AP Biosciences Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06723964
- Locations
- 🇨🇳
AP Biosciences, Inc., Taipei, Taiwan
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: AP402 (Part 1 Dose esclation)Drug: AP402 (Part 2 Dose Expansion)
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AP Biosciences Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT06669975
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
🇦🇺Macquarie University Clinical Trials Unit, Macquarie, New South Wales, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung Cancer (NSCLC)Locally Advanced or Metastatic Solid TumorsHead and Neck Squamous Cell Carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AP Biosciences Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT05473156
- Locations
- 🇨🇳
AP Biosciences Inc., Taipei City, Taiwan
News
No news found